Lp(a)は動脈硬化のリスクであり,動脈硬化性心血管疾患を有し,特に高値を示す例に対して治療を行うべきであるが,現在のところLDL-A以外に有効な方法はない.最近上市されたproprotein convertase subtilisin/kexin type 9(PCSK9)阻害剤は,Lp(a)を低下させる作用をもつが,LDL-Aの効果には遠く及ばない.しかしながら,高Lp(a)血症は,現在のところ,日本においてはLDL-Aの適応にはなっていない.
1) Seidel D:The HELP-system in the treatment of severe hypercholesterolaemia:acute and long-term experience. Adv Exp Me Biol 1991;285:155-9 2) Pokrovsky SN, Sussekov AV, Afanasieva OI, et al:Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp (a) apheresis):preliminary clinical data. Chem Phys Lipids 1994;67-68:323-30 3) Yamaguchi H, Lee YJ, Daida H, et al:Effectiveness of LDL-apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA):LDL-apheresis angioplasty restenosis trial (L-ART). Chem Phys Lipids 1994;67-68:399-403 4) Daida H, Lee YJ, Yokoi H, et al:Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994;73:1037-40 5) Ullrich H, Lackner K, Schmitz G:Lipoprotein (a)-apheresis in the secondary prevention of coronary heart disease. Transfus Sci 1996;17:511-7 6) Jaeger BR, Richter Y, Nagel D, et al, Group of Clinical I:Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-39 7) Leebmann J, Roeseler E, Julius U, et al, ProLiFe Study G:Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein (a)-hyperlipoproteinemia, and progressive cardiovascular disease:prospective observational multicenter study. Circulation 2013;128:2567-76 8) Rosada A, Kassner U, Vogt A, et al:Does regular lipid apheresis in patients with isolated elevated lipoprotein (a) levels reduce the incidence of cardiovascular events? Artif Organs 2014;38:135-41 9) Khan TZ, Pottle A, Pennell DJ, Barbir MS:The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein (a) in ischaemic heart disease and refractory angina. Global Cardiology Science & Practice 2014;2014:3-12